Brief: Prelude Therapeutics Announces Q3 Financial Results And Provides Business Update
14/11/2022 17:33
Nov 14 (Reuters) - Prelude Therapeutics Inc PRLD.O :
* PRELUDE THERAPEUTICS ANNOUNCES THIRD QUARTER 2022
FINANCIAL
RESULTS AND PROVIDES BUSINESS UPDATE
* CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES EXPECTED
TO
FUND MULTIPLE DATA CATALYSTS WITH A RUNWAY INTO Q4 OF 2024
* FOR THREE MONTHS ENDED SEPTEMBER 30, 2022, NET LOSS WAS
$30.0
MILLION, OR $0.63 PER SHARE OF COMMON STOCK
* Q3 EARNINGS PER SHARE VIEW $-0.64 -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNX6JNH8d
Further company coverage: PRLD.O
Recent news on Prelude Therapeutics Incorporated
See all newsBrief: Prelude Announces Clinical Trial Collaboration And Supply Agreement With Lilly To Evaluate KAT6A Selective Degrader PRT13722 In Combination With Verzenio® And Inluriyo® In Patients With HR+/HER2- Breast Cancer
U.S. RESEARCH ROUNDUP-Celcuity, Fluence Energy, Salesforce
Prelude Therapeutics Incorporated reports results for the quarter ended June 30 - Earnings Summary
Prelude Therapeutics Q2 revenue beats analyst expectations, net loss narrows
Prelude Therapeutics Incorporated expected to post a loss of 20 cents a share - Earnings Preview